NIKKEI 225
27,782.42+200.76(+0.73%)HANG SENG
26,175.06+701.18(+2.75%)CRUDE OIL
72.79+0.40(+0.55%)GOLD FUTURES
1,816.10+16.40(+0.91%)DOW
34,930.93-127.59(-0.36%)BTC-GBP
28,767.39+199.89(+0.70%)
Genmab A/S (GNMSF)
| Previous close | 452.42 |
| Open | 448.16 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 432.08 - 452.07 |
| 52-week range | 299.08 - 456.83 |
| Volume | 92 |
| Avg. volume | 416 |
| Market cap | 29.108B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | 32.14 |
| EPS (TTM) | 13.44 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 443.79 |
- Globe Newswire
Major Shareholder Announcement
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; July 21, 2021 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Artisan Partners Limited Partnership has informed us that, as of July 16, 2021, Artisan Partners Limited Partnership holds the voting rights to 3,261,591 shares in Genmab A/S, which amounts to 4.97% of the share capital and voting rights in Genmab A/S. About Genmab Genmab is an internationa
- Globe Newswire
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021
Company Announcement Net sales of DARZALEX® in the second quarter of 2021 totaled USD 1,433 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; July 21, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) formulation (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD
- Globe Newswire
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; July 06, 2021 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 47,974 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 660 shares at DKK 31.75,550 shares at DKK 220.40,9,487 shares at DKK 337.40,125 shares at DKK 466.20,1,875 shares
